Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilta-Talq Fusion Study in Relapsed/Refractory Multiple Myeloma
NCT07093554Phase 1Recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Dec 2025
- Primary completion
- Jul 2027
- Modality
- Gene Editing, Gene Silencing, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of talquetamab and ciltacabtagene autoleucel in multiple myeloma (MM), sponsored by Medical College of Wisconsin. Primary endpoint: Number of subjects without serious adverse events at 30 days. Started Dec 2025; status: recruiting.
02
Drugs
talquetamabciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07093554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07093554.